menu search

SGMT / Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH
Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows promising results in treating nonalcoholic steatohepatitis and acne. The company has a strong safety profile and sufficient cash to last until 2025. Read More
Posted: Sep 27 2023, 14:48
Author Name: Seeking Alpha
Views: 092136

SGMT News  

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

By GlobeNewsWire
October 18, 2023

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing no more_horizontal

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

By Seeking Alpha
September 27, 2023

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sagimet Biosciences Inc. develops FASN inhibitors for diseases related to dysfunctional lipid metabolism. Their lead candidate, Denifanstat, shows pro more_horizontal


Search within

Pages Search Results: